Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

Mohammad Hashemi , Gholamreza Bahari , Jarosław Markowski , Andrzej Małecki , Marek J Łos (1, 2, 3) , Saeid Ghavami

1 Silesian University of Technology
2 CBM - Centre de biophysique moléculaire
3 Le Studium Loire Valley Institute for Advanced Studies, 45000 Orléans, France

This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statistical analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate the strength of association. Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70-0.96, p = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, p < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, p = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, p = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67-0.86, p < 0.00001, G vs T) genetic model. The finding did not support an association between rs4957014 T>G polymorphism of PDCD6, and different cancers risk.

Mots clés: endometrial cancer; risk; cancer; PDCD6; meta-analysis

Domaines: Sciences du Vivant [q-bio]; Médecine humaine et pathologie

Mohammad Hashemi, Gholamreza Bahari, Jarosław Markowski, Andrzej Małecki, Marek J Łos, et al.. Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis. Oncotarget, 2018, 9 (37), pp.24857 - 24868. ⟨10.18632/oncotarget.25324⟩. ⟨hal-02506732⟩